Dannielle Appelhans - Aug 9, 2022 Form 4 Insider Report for Rubius Therapeutics, Inc. (RUBY)

Role: Chief Operating Officer
Signature: /s/ Maiken Keson-Brookes, as Attorney-in-Fact
Stock symbol: RUBY
Transactions as of: Aug 9, 2022
Transactions value $: -$4,590
Form type: 4
Date filed: 8/12/2022, 03:06 PM
Previous filing: Jul 19, 2022
Next filing: Feb 1, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RUBY	Common Stock	Options Exercise		+12.5K			12.5K	Aug 9, 2022	Direct	F1
transaction	RUBY	Common Stock	Sale	-$4.59K	-5.74K	-45.9%	$0.80^*	6.76K	Aug 10, 2022	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RUBY	Restricted Stock Units	Options Exercise	$0	-12.5K	-25%	$0.00	37.5K	Aug 9, 2022	Common Stock	12.5K		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2	Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units listed in Table II. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the reporting person.
F3	The shares underlying the restricted stock units vest in four equal annual installments beginning on August 9, 2022.